We are live on ! Find out more
NCM

Nantahala Capital Management Portfolio holdings

AUM $2.72B
1-Year Est. Return 121.58%
This Fund
S&P 500
This Quarter Est. Return
-6.99%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.71B
AUM Growth
-$39.6M
Cap. Flow
+$72.3M
Cap. Flow %
4.23%
Top 10 Hldgs %
57.63%
Holding
146
New
23
Increased
28
Reduced
39
Closed
16

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$28.5M
2
ESTA icon
Establishment Labs
ESTA
+$27.8M
3
PTON icon
Peloton Interactive
PTON
+$16.6M
4
SVRA icon
Savara
SVRA
+$15.3M
5
OPTN
OptiNose
OPTN
+$12.2M

Top Sells

Rank Stock Value
1
CASH icon
Pathward Financial
CASH
+$25.3M
2
LYRA
LYRA THERAPEUTICS INC
LYRA
+$17.5M
3
RDVT icon
Red Violet
RDVT
+$13.4M
4
DYN icon
Dyne Therapeutics
DYN
+$12.4M
5
GDEN
Golden Entertainment
GDEN
+$9.92M

Sector Composition

Rank Sector Weight
1 Healthcare 39.62%
2 Consumer Discretionary 7%
3 Financials 3.63%
4 Communication Services 3.53%
5 Technology 1.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THTX
76
DELISTED
Theratechnologies
THTX
$3.76M 0.22%
2,682,228
– –
ENVA icon
77
Enova International
ENVA
$6.29B
$3.49M 0.2%
55,999
-15,866
-22% -$968K
AYTU icon
78
AYTU BioPharma
AYTU
$25.5M
$3.17M 0.19%
1,086,812
– –
BCOV
79
DELISTED
Brightcove, Inc.
BCOV
$3.11M 0.18%
+1,313,768
New +$2.58M
ETON icon
80
Eton Pharmaceutcials
ETON
$1.2B
$3.1M 0.18%
+940,733
New +$3.29M
ACHV icon
81
Achieve Life Sciences
ACHV
$685M
$3.07M 0.18%
654,000
– –
DRIO icon
82
DarioHealth
DRIO
$74.7M
$2.85M 0.17%
119,566
-12,062
-9% -$342K
FOSL icon
83
Fossil Group
FOSL
$317M
$2.7M 0.16%
1,905,278
+598,940
+46% +$680K
NGNE icon
84
Neurogene
NGNE
$729M
$2.63M 0.15%
72,279
– –
NVNO
85
enVVeno Medical
NVNO
$6.78M
$2.51M 0.15%
13,653
-511
-4% -$89.2K
MIST icon
86
Milestone Pharmaceuticals
MIST
$157M
$2.31M 0.14%
1,750,000
– –
XTNT icon
87
Xtant Medical Holdings
XTNT
$62.6M
$2.26M 0.13%
3,580,000
-420,000
-11% -$335K
ABEO icon
88
CALL
Abeona Therapeutics
ABEO
$425M
$2.2M 0.13%
520,000
– –
CONN
89
DELISTED
Conn's Inc.
CONN
$2.18M 0.13%
1,973,315
+203,318
+11% +$654K
XBI icon
90
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$2.07M 0.12%
22,369
-19,700
-47% -$1.77M
SRZN icon
91
Surrozen
SRZN
$295M
$2.05M 0.12%
+187,206
New +$1.93M
TLPH icon
92
Talphera
TLPH
$73.2M
$1.77M 0.1%
1,992,519
– –
SRL icon
93
Scully Royalty
SRL
$89.4M
$1.7M 0.1%
239,197
– –
MAX icon
94
MediaAlpha
MAX
$830M
$1.63M 0.1%
123,564
-25,807
-17% -$475K
SGRP
95
DELISTED
SPAR Group
SGRP
$1.6M 0.09%
662,028
-217,161
-25% -$435K
ELDN icon
96
Eledon Pharmaceuticals
ELDN
$284M
$1.58M 0.09%
+600,000
New +$1.43M
ASPS icon
97
Altisource Portfolio Solutions
ASPS
$63.3M
$1.54M 0.09%
136,376
– –
UNCY icon
98
Unicycive Therapeutics
UNCY
$138M
$1.41M 0.08%
282,036
-51,523
-15% -$507K
ANEB
99
DELISTED
Anebulo Pharmaceuticals
ANEB
$1.4M 0.08%
511,073
– –
TIL icon
100
Instil Bio
TIL
$50.3M
$1.31M 0.08%
127,292
– –
2 3
4
5 6

Similar funds

TAM
Timucuan Asset Management Jacksonville, Florida $2.72B AUM 4.95% 1-Year Est. Return
XL
XN LP New York $2.72B AUM 46.67% 1-Year Est. Return
NB
Nicolet Bankshares Green Bay, Wisconsin $2.71B AUM 17.55% 1-Year Est. Return
PA
Profund Advisors Bethesda, Maryland $2.72B AUM 47.27% 1-Year Est. Return
BCM
Bowie Capital Management Richardson, Texas $2.71B AUM 5.42% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $2.7B AUM 23.62% 1-Year Est. Return
GC
Giverny Capital Montreal, Quebec, Canada $2.73B AUM 14.09% 1-Year Est. Return

Nantahala Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Nantahala Capital Management held 146 positions worth $1.71B, down 2.3% from $1.75B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Nantahala Capital Management deployed $72.3M of net new capital in Q2 2024, opening 23 new positions and adding to 28 existing holdings. Its largest new stake was The Bancorp: 337,846 shares worth $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was Pathward Financial, an estimated $25.3M trimmed.

  • Nantahala Capital Management's largest Q2 2024 buy was The Bancorp: 337,846 shares worth $12.8M.
  • Nantahala Capital Management added most to Soleno Therapeutics in Q2 2024, an estimated $28.5M increase.
  • Nantahala Capital Management's biggest Q2 2024 reduction was Pathward Financial, cutting an estimated $25.3M.
  • Nantahala Capital Management fully exited LYRA THERAPEUTICS INC in Q2 2024, selling an estimated $17.5M.
  • Nantahala Capital Management's ten largest holdings make up 58% of its $1.71B portfolio in Q2 2024.
  • Nantahala Capital Management opened 23 new positions and closed 16 in Q2 2024.
  • Nantahala Capital Management's portfolio value fell 2.3% quarter-over-quarter to $1.71B.

Based on Nantahala Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.